Seattle Genetics, Inc.
| Article | Date | Source |
|---|
| Seattle Genetics rare cancer drug sails through accelerated approval | -- | Nature Biotechnology |
| Seattle Genetics Reports First Quarter 2013 Financial Results | May 07, 2013 | Biotech News - Business Wire |
| Seattle Genetics Reports First Quarter 2013 Financial Results | May 07, 2013 | Pharma News - Business Wire |
| Seattle Genetics and Collaborators Highlight Multiple Antibody-Drug Conjugate (ADC) Programs and Technology Advances at AACR | April 09, 2013 | Biotech News - Business Wire |
| Seattle Genetics and Collaborators Highlight Multiple Antibody-Drug Conjugate (ADC) Programs and Technology Advances at AACR | April 09, 2013 | Pharma News - Business Wire |
| Seattle Genetics to Host Conference Call and Webcast Discussion of Fourth Quarter and Year 2012 Financial Results on February 12, 2013 | January 29, 2013 | Pharma News - PharmiWeb |
| Seattle Genetics to Host Conference Call and Webcast Discussion of Fourth Quarter and Year 2012 Financial Results on February 12, 2013 | January 29, 2013 | Biotech News - Business Wire |
| Seattle Genetics to Host Conference Call and Webcast Discussion of Fourth Quarter and Year 2012 Financial Results on February 12, 2013 | January 29, 2013 | Pharma News - Business Wire |
| Seattle Genetics gets undisclosed milestone payments | October 09, 2012 | Health News - BizJournals.com |
| Seattle Genetics Achieves Milestones as Genentech Advances Two Antibody-Drug Conjugates (ADCs) into Phase II Development | October 09, 2012 | Pharma News - Business Wire |
| Millennium and Seattle Genetics Highlight Data from ADCETRIS® (Brentuximab Vedotin) Trial in Patients with Newly Diagnosed Systemic Anaplastic Large Cell Lymphoma | October 01, 2012 | Pharma News - Business Wire |
| Seattle Genetics and Millennium Complete Enrollment in Phase III AETHERA Trial of ADCETRIS® for Post-Transplant Patients with Hodgkin Lymphoma | September 25, 2012 | Pharma News - Business Wire |
| Seattle Genetics Announces ADCETRIS® Receives Positive CHMP Opinion for Conditional Approval in European Union | July 20, 2012 | Pharma News - Business Wire |
| Cramer Interviews Seattle Genetics CEO | June 05, 2012 | Health News - CNBC |
| Seattle Genetics Announces Health Canada Accepts ADCETRIS® New Drug Submission for Review | May 23, 2012 | Pharma News - Business Wire |
| Seattle Genetics Follows the Science, Taking on Rare Lymphoma No. 3 | May 23, 2012 | Xconomy Life Sciences |
| Seattle Genetics to Present ADCETRIS® and ASG-5ME Data at ASCO Annual Meeting | May 16, 2012 | Pharma News - Business Wire |
| Seattle Genetics to Present at Bank of America Merrill Lynch Health Care Conference | May 11, 2012 | Pharma News - Business Wire |
| Seattle Genetics Announces Data from Investigator Trial of ADCETRIS™ in Relapsed Cutaneous T-Cell Lymphoma | May 10, 2012 | Pharma News - Business Wire |
| Seattle Genetics pares Q1 loss, stock slips | May 09, 2012 | Health News - BizJournals.com |
| Seattle Genetics Misses 1st Quarter Sales Estimate, But Sees $1B Future | May 08, 2012 | Xconomy Life Sciences |
| Seattle Genetics Reports First Quarter 2012 Financial Results | May 08, 2012 | Pharma News - Business Wire |
| Millennium and Seattle Genetics Initiate Global Phase 3 Trial of ADCETRIS™ in Patients with CD30-Expressing Relapsed Cutaneous T-cell Lymphoma | May 07, 2012 | Pharma News - Business Wire |
| Seattle Genetics to Host Conference Call and Webcast Discussion of First Quarter 2012 Financial Results on May 8, 2012 | April 24, 2012 | Pharma News - Business Wire |
| Seattle Genetics Demonstrates Continued Leadership in Antibody-Drug Conjugates at AACR | April 03, 2012 | Pharma News - Business Wire |
| Seattle Genetics to Present at Needham Healthcare Conference | March 29, 2012 | Pharma News - Business Wire |
| Seattle Genetics Announces Pivotal ADCETRIS™ (Brentuximab Vedotin) Hodgkin Lymphoma Study Published in Journal of Clinical Oncology | March 26, 2012 | Pharma News - Business Wire |
| Seattle Genetics Appoints Dr. Nancy Simonian to Board of Directors | March 21, 2012 | Pharma News - Business Wire |
| Seattle Genetics Digs Deeper Into the Proverbial Haystack | March 13, 2012 | Xconomy Life Sciences |
| Seattle Genetics Digs Into the Haystack, Looking for More than One Needle | March 13, 2012 | Xconomy Life Sciences |
| Seattle Genetics Found Its Needle in the Haystack, Sparking Big Push For More | March 13, 2012 | Xconomy Life Sciences |
| Seattle Genetics Gets New Commercial Boss for Early Days of Adcetris | February 23, 2012 | Xconomy Life Sciences |
| Seattle Genetics Gets New Commercial Boss for Early Days of Adcetris | February 23, 2012 | Xconomy Life Sciences |
| Seattle Genetics Provides Update on Commercial Leadership | February 23, 2012 | Pharma News - Business Wire |
| Seattle Genetics 2011 net loss more than double over 2010, but Q4 result improves | February 14, 2012 | Health News - BizJournals.com |
| Seattle Genetics Reports Fourth Quarter and Year 2011 Financial Results | February 13, 2012 | Pharma News - Business Wire |
| Seattle Genetics to Host Conference Call and Webcast Discussion of Fourth Quarter and Year 2011 Financial Results on February 13, 2012 | February 01, 2012 | Pharma News - Business Wire |
| Seattle Genetics Announces Data from ADCETRIS™ in Cutaneous T-Cell Lymphoma and Peripheral T-Cell Lymphoma | January 26, 2012 | Pharma News - Business Wire |
| Seattle Genetics and Millennium Report Data from Phase I Trial of ADCETRIS™ in Front-line Mature T-Cell Lymphomas | January 26, 2012 | Pharma News - Business Wire |
| Seattle Genetics has the Lowest Free Cash Flow Per Share in the Biotechnology Industry (SGEN, ARIA, ORCH, RGEN, OREX) | January 18, 2012 | Biotechnology - Moreover |
| Seattle Genetics ([[SGEN -4.8%) and Takeda Pharmaceutical ([[TKPYY.PK -1.00%) dip after the FDA says it's seen three cases of serious brain infection among patients being treated with their jointly-produced lymphoma drug Adcetris, and strengthened the | January 13, 2012 | Pharmaceutical - Moreover |
| Seattle Genetics to Present at the J.P. Morgan Healthcare Conference (BIZ) | January 04, 2012 | Biotechnology - Moreover |
| Seattle Genetics is Among the Companies in the Biotechnology Industry With the Lowest Free Cash Flow Per Share (SGEN, ARIA, ORCH, RGEN, OREX) | December 19, 2011 | Biotechnology - Moreover |
| Seattle Genetics And Takeda Pharmaceutical Company Limited's Millennium Report Data From Phase I Trial Of ADCETRIS (Brentuximab Vedotin) In Front-line Hodgkin Lymphoma | December 14, 2011 | Pharmaceutical - Moreover |
| Seattle Genetics and Millennium Report Data from Phase I Trial of ADCETRIS(TM) (Brentuximab Vedotin) in Front-line Hodgkin Lymphoma at ASH Annual Meeting - Phase III Front-line Trial Planned in Advanced Stage Hodgkin Lymphoma Patients - | December 13, 2011 | Pharmaceutical - Moreover |
| Seattle Genetics and Millennium Report Data from Phase I Trial of ADCETRIS™ (Brentuximab Vedotin) in Front-line Hodgkin Lymphoma at ASH Annual Meeting | December 13, 2011 | Pharma News - Business Wire |
| Seattle Genetics Reports Data From Multiple Presentations on ADCETRIS™ (Brentuximab Vedotin) at ASH Annual Meeting | December 12, 2011 | Pharma News - Business Wire |
| Seattle Genetics and Millennium Highlight Pivotal Data on ADCETRIS™ (Brentuximab Vedotin) in Relapsed or Refractory Systemic ALCL at ASH Annual Meeting | December 12, 2011 | Pharma News - Business Wire |
| Seattle Genetics to Present at Upcoming Investor Conference | December 07, 2011 | Pharma News - Business Wire |
| Seattle Genetics Sees Case of PML, Causing Market Twitch | December 01, 2011 | Xconomy Life Sciences |
| Seattle Genetics Sees 2nd Case of PML, Causing Market to Twitch, then Relax | December 01, 2011 | Xconomy Life Sciences |
| Seattle Genetics Falls 1.99% on Heavy Volume: Watch For Potential Rebound (SGEN) | November 21, 2011 | Biotechnology - Moreover |
| Look for Shares of Seattle Genetics to Potentially Rebound after Yesterday's 1.94% Sell Off (SGEN) | November 15, 2011 | Biotechnology - Moreover |
| Seattle Genetics and Millennium Announce Presentation of ADCETRIS™ Data at American Society of Hematology Annual Meeting | November 08, 2011 | Pharma News - Business Wire |
| Seattle Genetics had the Lowest Relative Performance in the Biotechnology ... | November 08, 2011 | Biotechnology - Moreover |
| SEATTLE GENETICS, INC.: Seattle Genetics to Present at Two Upcoming Investor Conferences | November 07, 2011 | Biotechnology - Moreover |
| SEATTLE GENETICS, INC. : Seattle Genetics to Present at Two Upcoming Investor Conferences | November 07, 2011 | Biotechnology - Moreover |
| Seattle Genetics beats Wall Street predictions for new cancer drug | November 04, 2011 | Health News - BizJournals.com |
| Seattle Genetics Reports Third Quarter 2011 Financial Results | November 03, 2011 | Pharma News - Business Wire |
| Seattle Genetics Beats Expectations With $10M Sales in Lymphoma Drug Debut | November 03, 2011 | Xconomy Life Sciences |
| Seattle Genetics Appoints Vice President, Medical Affairs and Announces Vice President, Quality Management Promotion | October 26, 2011 | Pharma News - Business Wire |
| Seattle Genetics Announces Initiation of a Phase II Clinical Trial of ADCETRIS™ in CD30-Positive Non-Lymphoma Malignancies | October 25, 2011 | Pharma News - Business Wire |
| Analyst: Seattle Genetics should outperform forecasts | October 21, 2011 | Health News - BizJournals.com |
| Analyst: Seattle Genetics on Pace to Smash Wall Street Forecast with Lymphoma Drug Rollout | October 20, 2011 | Xconomy Life Sciences |
| Seattle Genetics to Host Conference Call and Webcast Discussion of Third Quarter 2011 Financial Results on November 3, 2011 | October 20, 2011 | Pharma News - Business Wire |
| Zishen Fan sentenced to 18 months in Seattle Genetics insider trading case | October 08, 2011 | Health News - BizJournals.com |
| Resumen: Millennium y Seattle Genetics presentan datos clínicos sobre ADCETRISTM (Brentuximab Vedotin) en pacientes pediátricos en reunión anual de la EMCC | September 26, 2011 | Pharma News - Business Wire |
| Millennium et Seattle Genetics présentent, à l’occasion de la réunion annuelle de l’EMCC, des données cliniques concernant l’utilisation d’ADCETRIS™ (Brentuximab Vedotin) chez les patients pédiatriques | September 24, 2011 | Pharma News - Business Wire |
| Millennium und Seattle Genetics legen auf der EMCC-Jahrestagung klinische Daten zu ADCETRIS™ (Brentuximab Vedotin) bei pädiatrischen Patienten vor | September 24, 2011 | Pharma News - Business Wire |
| Riassunto: Millennium e Seattle Genetics presentano dati clinici su ADCETRIS™ (brentuximab vedotin) nei pazienti pediatrici all'assemblea annuale dell'EMCC | September 24, 2011 | Pharma News - Business Wire |
| Samenvatting: Millennium en Seattle Genetics presenteren klinische gegevens over ADCETRIS (brentuximab vedotin) bij pediatrische patiënten op jaarlijkse bijeenkomst EMCC | September 24, 2011 | Pharma News - Business Wire |
| Millennium and Seattle Genetics Present Clinical Data on ADCETRIS™ (Brentuximab Vedotin) in Pediatric Patients at EMCC Annual Meeting | September 24, 2011 | Pharma News - Business Wire |
| Seattle Genetics and OBT Establish Cancer Antibody-Drug Conjugate Collaboration | September 13, 2011 | Inside Industry - Gen |
| Seattle Genetics and Oxford BioTherapeutics to Collaborate on Antibody-Drug Conjugates for Cancer -Companies to combine proprietary technologies to generate novel ADC product candidates- | September 13, 2011 | Biotechnology - Moreover |
| Seattle Genetics and Oxford BioTherapeutics to Collaborate on Antibody-Drug Conjugates for Cancer | September 13, 2011 | Pharma News - Business Wire |
| Seattle Genetics to Present at Two Upcoming Investor Conferences | September 08, 2011 | Pharma News - Business Wire |
| Seattle Genetics cancer drug price may top $100,000
(Reuters)
| August 22, 2011 | Yahoo Biotech News |
| Seattle Genetics Reports Second Quarter 2011 Financial Results | August 04, 2011 | Pharma News - Business Wire |
| Seattle Genetics to Host Conference Call and Webcast Discussion of Second Quarter 2011 Financial Results on August 4, 2011 | July 26, 2011 | Pharma News - Business Wire |
| Seattle Genetics stock drops; CEO still confident | July 15, 2011 | Health News - BizJournals.com |
| Seattle Genetics wins FDA panel's OK | July 14, 2011 | Health News - BizJournals.com |
| Seattle Genetics Announces Unanimous Recommendations from FDA Advisory Committee in Favor of Accelerated Approval of ADCETRIS™ for Post-Transplant Relapsed Hodgkin Lymphoma and Relapsed or Refractory Systemic ALCL | July 14, 2011 | Pharma News - Business Wire |
| FDA panel backs Seattle Genetics drug for lymphoma | July 14, 2011 | Health News - CNBC |
| FDA panel backs Seattle Genetics drug for lymphoma
(Reuters)
| July 14, 2011 | Yahoo Biotech News |
| Seattle Genetics Lymphoma Drug Gets Second Green Light from FDA Panel | July 14, 2011 | Xconomy Life Sciences |
| UPDATED: Seattle Genetics lymphoma drug gets FDA panel nod | July 14, 2011 | FierceBiotech |
| Seattle Genetics Wins Unanimous OK for Lymphoma Drug from FDA Panel | July 14, 2011 | Xconomy Life Sciences |
| Seattle Genetics Wins Unanimous FDA Panel Recommendation for Hodgkin’s Disease | July 14, 2011 | Xconomy Life Sciences |
| Seattle Genetics drug gets FDA panel nod for Hodgkin patients | July 14, 2011 | FierceBiotech |
| Trading in Seattle Genetics shares halted | July 14, 2011 | Health News - BizJournals.com |
| Trading of Seattle Genetics Common Stock Halted | July 14, 2011 | Pharma News - Business Wire |
| Guilty plea in Seattle Genetics insider trading case | July 12, 2011 | Health News - BizJournals.com |
| Trial size may limit use of Seattle Genetics drug
(Reuters)
| July 12, 2011 | Yahoo Biotech News |
| FDA eyes trial size for Seattle Genetics cancer drug | July 12, 2011 | Health News - CNBC |
| Seattle Genetics takes step closer with FDA review of lymphoma drug | July 12, 2011 | FierceBiotech |
| FDA eyes trial size for Seattle Genetics cancer drug
(Reuters)
| July 12, 2011 | Yahoo Biotech News |
| Seattle Genetics Announced It Will Recieve A $5M Milestone P | June 28, 2011 | Pharmaceutical - Moreover |
| Seattle Genetics gets $5M milestone payment | June 27, 2011 | Health News - BizJournals.com |
| Seattle Genetics (SGEN) to Receive Multi-Million Milestone Under ADCETRISTM Collaboration | June 27, 2011 | Pharmaceutical - Moreover |
| Seattle Genetics Achieves Milestone Under Millennium Collaboration for European Medicines Agency Acceptance of Brentuximab Vedotin MAA | June 27, 2011 | Pharma News - Business Wire |
| Seattle Genetics promotes Eric Dobmeier to COO | June 17, 2011 | Health News - BizJournals.com |
| Seattle Genetics Announces Promotion of Eric Dobmeier to Chief Operating Officer | June 17, 2011 | Pharma News - Business Wire |
| FDA committee to review Seattle Genetics cancer drug applications in July | June 16, 2011 | Health News - BizJournals.com |
| Seattle Genetics Announces FDA Advisory Committee to Review Brentuximab Vedotin for the Treatment of Relapsed or Refractory Hodgkin Lymphoma and Systemic ALCL | June 16, 2011 | FDA News - Business Wire |
| Seattle Genetics to Present Brentuximab Vedotin and Dacetuzumab Clinical Data at International Conference on Malignant Lymphoma | June 15, 2011 | Pharma News - Business Wire |
| Millennium and Seattle Genetics Present Clinical Data on ADCETRIS™ (Brentuximab Vedotin) in Hodgkin Lymphoma at EHA Annual Meeting | June 11, 2011 | Pharma News - Business Wire |
| Millennium and Seattle Genetics Present Clinical Data on ADCETRIS™ (Brentuximab Vedotin) in Systemic ALCL at EHA Annual Meeting | June 10, 2011 | FDA News - Business Wire |
| Seattle Genetics and Agensys, an Affiliate of Astellas, Announce Co-Development of Second Antibody-Drug Conjugate (ADC) Under Existing Collaboration | June 09, 2011 | Pharma News - Business Wire |
| Seattle Genetics and Millennium Present Updated Brentuximab Vedotin (SGN-35) Data at ASCO Annual Meeting | June 06, 2011 | Pharma News - Business Wire |
| Seattle Genetics Presents SGN-75 Clinical Data at ASCO Annual Meeting | June 06, 2011 | Pharma News - Business Wire |
| Millennium and Seattle Genetics Announce Brentuximab Vedotin (SGN-35) Presentations at 16th Congress of the European Hematology Association | May 27, 2011 | Pharma News - Business Wire |
| Seattle Genetics to Present Brentuximab Vedotin and SGN-75 Clinical Data at the American Society of Clinical Oncology Annual Meeting | May 19, 2011 | Pharma News - Business Wire |
| Seattle Genetics reports 1Q loss on revenue dip | May 06, 2011 | Health News - CNBC |
| Seattle Genetics posts loss for Q1 | May 06, 2011 | Health News - BizJournals.com |
| Seattle Genetics Reports First Quarter 2011 Financial Results | May 05, 2011 | Pharma News - Business Wire |
| Seattle Genetics shares rise in heavy trading | May 04, 2011 | Health News - BizJournals.com |
| Seattle Genetics: FDA reviewing cancer drug applications | May 02, 2011 | Health News - BizJournals.com |
| Seattle Genetics says FDA is reviewing cancer drug | May 02, 2011 | Health News - CNBC |
| Seattle Genetics Announces FDA Accepts Brentuximab Vedotin BLAs for Filing and Grants Priority Review for Relapsed or Refractory Hodgkin Lymphoma and Systemic ALCL | May 02, 2011 | FDA News - Business Wire |
| Seattle Genetics to Host Conference Call and Webcast Discussion of First Quarter 2011 Financial Results on May 5, 2011 | April 26, 2011 | Pharma News - Business Wire |
| Genmab, Seattle Genetics Expand ADC Pact | April 19, 2011 | Contract Pharma |
| Seattle Genetics and Genmab expand collaboration | April 19, 2011 | Health News - CNBC |
| Genmab and Seattle Genetics Expand Antibody-Drug Conjugate Collaboration | April 19, 2011 | Pharma News - Business Wire |
| Seattle Genetics Appoints Vice President, Corporate Development and Announces Management Promotion | April 18, 2011 | Pharma News - Business Wire |
| Seattle Genetics Announces Tenth Collaborator ADC Program in Clinical Development | April 13, 2011 | Pharma News - Business Wire |
| Seattle Genetics Reports Brentuximab Vedotin (SGN-35) Data at EBMT Annual Meeting | April 06, 2011 | Pharma News - Business Wire |
| Seattle Genetics Highlights ADC Technology Research at AACR | April 05, 2011 | Pharma News - Business Wire |
| Lightning Round: Baidu, Accuride, Seattle Genetics and More | March 25, 2011 | Biotechnology - Moreover |
| Seattle Genetics Enters Antibody-Drug Conjugate Collaboration with Abbott | March 25, 2011 | Biotechnology - Moreover |
| Seattle Genetics enters into ADC collaboration agreement with Abbott | March 23, 2011 | Pharmaceutical - Moreover |
| Seattle Genetics in $8M deal with Abbott | March 22, 2011 | Health News - BizJournals.com |
| Seattle Genetics strikes again with $208M ADC deal with Abbott | March 22, 2011 | FierceBiotech |
| Seattle Genetics Announces Antibody-Drug Conjugate Collaboration with Abbott | March 22, 2011 | Pharma News - Business Wire |
| Seattle Genetics gets fee in Takeda contract | March 15, 2011 | Pharmaceutical - Moreover |
| Seattle Genetics gets fee for Millennium collaboration | March 15, 2011 | Health News - BizJournals.com |
| Seattle Genetics and Millennium Expand Antibody-Drug Conjugate Collaboration | March 15, 2011 | Pharma News - Business Wire |
| Seattle Genetics to Present at Upcoming Investor Conferences (BIZ) | March 03, 2011 | Biotechnology - Moreover |
| Seattle Genetics and Millennium Announce Initiation of a Phase I Clinical Trial of Brentuximab Vedotin in Combination with Chemotherapy for Front-line Systemic ALCL | March 01, 2011 | Pharma News - Business Wire |
| Seattle Genetics seeks tumor drug nod | February 28, 2011 | Health News - BizJournals.com |
| Seattle Genetics Submits BLA to FDA for Brentuximab Vedotin in Relapsed or Refractory Hodgkin Lymphoma and Systemic ALCL | February 28, 2011 | FDA News - Business Wire |
| Seattle Genetics Announces Exercise of Over-Allotment Option | February 03, 2011 | Pharma News - Business Wire |
| Seattle Genetics needs funds | February 03, 2011 | Biotechnology - Moreover |
| Seattle Genetics Reloads, Uptake Ups and Leaves, PhysioSonics Raises Cash, & More Seattle-Area Life Sciences News | February 03, 2011 | Xconomy Life Sciences |
| Seattle Genetics to Host Conference Call and Webcast Discussion of Fourth Quarter and Year 2010 Financial Results on February 8, 2011 | February 02, 2011 | Pharma News - Business Wire |
| Seattle Genetics offering $155 million in stock | February 02, 2011 | Health News - CNBC |
| Seattle Genetics raises $155M; Chelsea splits trial for Northera; | February 02, 2011 | FierceBiotech |
| Seattle Genetics tries to raise $155M | February 02, 2011 | Health News - BizJournals.com |
| Seattle Genetics Reloads Cash Reserves With $155M, On Cusp of Selling First Drug | February 02, 2011 | Xconomy Life Sciences |
| Seattle Genetics Prices Public Offering of Common Stock | February 02, 2011 | Pharma News - Business Wire |
| Seattle Genetics plans public stock offering | February 01, 2011 | Health News - CNBC |
| Seattle Genetics Announces Proposed Public Offering of Common Stock | February 01, 2011 | Pharma News - Business Wire |
| Seattle Genetics Manager Accused of Insider Trading, Bristol Stays in Seattle, Amgen Buys BioVex, & More Seattle-Area Life Sciences News | January 27, 2011 | Xconomy Life Sciences |
| SEC Accuses Seattle Genetics Employee of Insider Trading | January 21, 2011 | Xconomy Life Sciences |
| Seattle Genetics Gets Some Love on National TV, as Cancer Drug Nears Market | January 14, 2011 | Xconomy Life Sciences |
| Seattle Genetics Rises On CEO's Appearance On CNBC (SGEN) | January 11, 2011 | Biotechnology - Moreover |
| Seattle Genetics to Present at J.P. Morgan Healthcare Conference | January 10, 2011 | Biotechnology - Moreover |
| Seattle Genetics announces Pfizer collaboration | January 06, 2011 | Health News - CNBC |
| Seattle Genetics Gets $8M From Pfizer | January 06, 2011 | Xconomy Life Sciences |
| Seattle Genetics scores $208M Pfizer pact for ADC tech | January 06, 2011 | FierceBiotech |
| Seattle Genetics Joins With Pfizer On Cancer Drug Technology | January 06, 2011 | Health News - Fox Business |
| Seattle Genetics Announces Antibody-Drug Conjugate Collaboration with Pfizer | January 06, 2011 | Pharma News - Business Wire |
| Seattle Genetics Announces Webcast of Presentation at J.P. Morgan Healthcare Conference | January 04, 2011 | Pharma News - Business Wire |
| Seattle Genetics to Webcast Presentation at 2010 Deutsche Bank BioFEST | December 13, 2010 | Pharma News - Business Wire |
| Seattle Genetics and Millennium Report Positive Data from Phase II Trial of Brentuximab | December 08, 2010 | Pharmaceutical - Moreover |
| Seattle Genetics `Guided Missile' Drug Blasts Rare Lymphoma in New Study | December 08, 2010 | Pharmaceutical - Moreover |
| Seattle Genetics â??Guided Missileâ?? Blasts Rare Lymphoma | December 07, 2010 | Pharmaceutical - Moreover |
| Seattle Genetics and Millennium announce positive data from SGN-35 Phase II trial | December 07, 2010 | Pharmaceutical - Moreover |
| Seattle Genetics (SGEN) and Millennium Announce Positive Phase II SGN-35 Data in | December 07, 2010 | Pharmaceutical - Moreover |
| Seattle Genetics ($SGEN) delivers second round of stellar SGN-35 data | December 07, 2010 | FierceBiotech |
| Seattle Genetics and Millennium Report Positive Data from Phase II Trial of Brentuximab Vedotin (SGN-35) in Relapsed or Refractory ALCL at ASH Annual Meeting | December 07, 2010 | Pharma News - Business Wire |
| Seattle Genetics delivers second round of stellar SGN-35 data | December 07, 2010 | FierceBiotech |
| Study: Seattle Genetics and Takeda's drug leads to lymphoma remission | December 06, 2010 | Pharmaceutical - Moreover |
| Seattle Genetics ($SGEN) plots FDA app on promising PhIII cancer data | December 06, 2010 | FierceBiotech |
| Seattle Genetics ($SGEN) unveils pivotal cancer data, plans for FDA app | December 06, 2010 | FierceBiotech |
| Seattle Genetics to submit lymphoma drug to FDA
(Reuters)
| December 06, 2010 | Yahoo Biotech News |
| Seattle Genetics e Millennium presentano al Meeting annuale ASH i dati positivi dallo studio pilota di Brentuximab Vedotin (SGN-35) nel linfoma di Hodgkin recidivante o refrattario | December 05, 2010 | Marketwire - Pharma and Biotech |
| Seattle Genetics et Millennium Report prsentent lors du congrs annuel de l'ASH des donnes positives pour l'essai pivot valuant le brentuximab vedotin (SGN-35) chez les patients souffrant d'un lymphome de Hodgkin rcidivant ou rfractaire | December 05, 2010 | Marketwire - Pharma and Biotech |
| Seattle Genetics y Millennium presentan datos positivos del ensayo fundamental con brentuximab vedotina (SGN-35) para el linfoma hodgkiniano recidivante o refractario en la Reunin Anual de la ASH | December 05, 2010 | Marketwire - Pharma and Biotech |
| Seattle Genetics und Millennium geben auf der ASH-Jahrestagung positive Ergebnisse der Pivotalstudie zu Brentuximab Vedotin (SGN-35) beim rezidivierten oder refraktren Hodgkin-Lymphom bekannt | December 05, 2010 | Marketwire - Pharma and Biotech |
| Seattle Genetics and Millennium Report Positive Data from Pivotal Trial of Brentuximab Vedotin (SGN-35) in Relapsed or Refractory Hodgkin Lymphoma at ASH Annual Meeting | December 05, 2010 | Pharma News - Business Wire |
| Remission rate 34 pct for Seattle Genetics drug
(Reuters)
| December 05, 2010 | Yahoo Biotech News |
| Seattle Genetics Leads Roche in Race to Develop Cancer Combo | December 02, 2010 | Pharmaceutical - Moreover |
| Seattle Genetics Leads Roche in Cancer Combo Race | December 01, 2010 | Pharmaceutical - Moreover |
| Seattle Genetics announces management changes | December 01, 2010 | Biotechnology - Moreover |
| Seattle Genetics ($SGEN) angling for the lead in combo cancer drug race | December 01, 2010 | FierceBiotech |
| Seattle Genetics Announces Additions to Commercial Leadership Team | November 30, 2010 | Pharma News - Business Wire |
| Seattle Genetics to Present at JMP Securities Healthcare Focus Conference | November 29, 2010 | Biotechnology - Moreover |
| Seattle Genetics to Present at Piper Jaffray Health Care Conference | November 29, 2010 | Pharma News - Business Wire |
| Seattle Genetics: Stock on the Move Lower, Down 1% (SGEN) | November 12, 2010 | Biotechnology - Moreover |
| Seattle Genetics and Millennium to Present Brentuximab Vedotin Clinical Data | November 08, 2010 | Pharmaceutical - Moreover |
| Seattle Genetics and Millennium to Present Brentuximab Vedotin (SGN-35) Clinical Data at American Society of Hematology Annual Meeting | November 08, 2010 | Pharma News - Business Wire |
| Seattle Genetics Reports Third Quarter 2010 Financial Results | November 01, 2010 | Pharma News - Business Wire |
| Compugen, Seattle Genetics sign cancer drug deal | October 29, 2010 | Health News - CNBC |
| Seattle Genetics to Present at Oppenheimer Healthcare Conference | October 29, 2010 | Pharma News - Business Wire |
| Seattle Genetics and Millennium to Highlight Brentuximab Vedotin (SGN-35) at the International Symposium on Hodgkin Lymphoma | October 25, 2010 | Biotech News - Business Wire |
| Seattle Genetics Schedules Conference Call and Webcast for 3Q 2010 Financial Results | October 24, 2010 | Biotechnology - Moreover |
| Agensys, an Affiliate of Astellas, and Seattle Genetics Announce Initiation of Phase I Clinical Trial of ASG-5ME for Prostate Cancer | October 20, 2010 | Pharma News - Business Wire |
| Seattle Genetics to Host Conference Call and Webcast Discussion of Third Quarter 2010 Financial Results on November 1, 2010 | October 19, 2010 | Pharma News - Business Wire |
| Seattle Genetics and Takeda's lymphoma drug performs well in studies | October 14, 2010 | Pharmaceutical - Moreover |
| Seattle Genetics Nails 2nd Trial, Bristol Clinches Zymo Buyout, Halosource Goes Public, & More Seattle-Area Life Sciences News | October 14, 2010 | Xconomy Life Sciences |
| Seattle Genetics and Takeda's lymphoma drug performs well in study | October 12, 2010 | Pharmaceutical - Moreover |
| Seattle Genetics says cancer drug met study goal | October 11, 2010 | Health News - CNBC |
| Seattle Genetics says lymphoma drug test goes well | October 11, 2010 | Health News - BizJournals.com |
| Seattle Genetics and Millennium Announce Positive Top-Line Brentuximab Vedotin (SGN-35) Data from Phase II Trial in Relapsed or Refractory ALCL | October 11, 2010 | Pharma News - Business Wire |
| Seattle Genetics Reports Preliminary Data from Phase I Clinical Trial of SGN-75 | October 11, 2010 | Pharma News - Business Wire |
| Seattle Genetics to Present SGN-75 Clinical Data at the European Society for Medical Oncology (ESMO) Congress | October 04, 2010 | Pharma News - Business Wire |
| Study shows efficacy of Seattle Genetics and Takeda's cancer drug | September 28, 2010 | Pharmaceutical - Moreover |
| Seattle Genetics cancer drug meets study goal | September 27, 2010 | Health News - CNBC |
| Seattle Genetics reports positive lymphoma drug test results | September 27, 2010 | Health News - BizJournals.com |
| Seattle Genetics and Millennium Announce Positive Top-Line Brentuximab Vedotin (SGN-35) Data from Pivotal Trial in Relapsed and Refractory Hodgkin Lymphoma | September 27, 2010 | FDA News - Business Wire |
| Seattle Genetics to release lymphoma data Monday | September 24, 2010 | Biotechnology - Moreover |
| Seattle Genetics to release lymphoma trial data | September 24, 2010 | Health News - BizJournals.com |
| Seattle Genetics to Host Conference Call and Webcast on September 27, 2010 Regarding Top-line Data from Brentuximab Vedotin (SGN-35) Pivotal Hodgkin Lymphoma Clinical Trial | September 24, 2010 | Pharma News - Business Wire |
| Seattle Genetics Snags Genmab Deal | September 14, 2010 | Xconomy Life Sciences |
| Genmab, Seattle Genetics ink cancer research deal | September 14, 2010 | FierceBiotech |
| Genmab and Seattle Genetics Enter into Antibody-Drug Conjugate Research Collaboration | September 14, 2010 | Pharma News - Business Wire |
| Genmab, Seattle Genetics Enter ADC Alliance | September 14, 2010 | Contract Pharma |
| Seattle Genetics and Genmab in cancer drug deal | September 14, 2010 | Health News - CNBC |
| Seattle Genetics leukemia drug fails study | September 13, 2010 | Health News - CNBC |
| Seattle Genetics leukemia drug fails in test | September 13, 2010 | Health News - BizJournals.com |
| Seattle Genetics will shelve AML drug after PhIIb failure | September 13, 2010 | FierceBiotech |
| Seattle Genetics Announces Phase IIb Trial of Lintuzumab (SGN-33) in Patients with Acute Myeloid Leukemia (AML) Did Not Meet Primary Endpoint | September 13, 2010 | Pharma News - Business Wire |
| Seattle Genetics to Host Conference Call and Webcast on September 13, 2010 to Discuss Top-line... | September 10, 2010 | Biotechnology - Moreover |
| Seattle Genetics to unveil leukemia data on Monday | September 10, 2010 | Biotechnology - Moreover |
| Seattle Genetics to Host Conference Call and Webcast on September 13, 2010 to Discuss Top-line Data from Lintuzumab (SGN-33) Pha | September 10, 2010 | Biotechnology - Moreover |
| Seattle Genetics to Host Conference Call and Webcast on September 13, 2010 to Discuss Top-line Data from Lintuzumab (SGN-33) Phase IIb Clinical Trial | September 10, 2010 | Pharma News - Business Wire |
| Seattle Genetics Achieves Milestone under Antibody-Drug Conjugate Collaboration with Agensys, an Affiliate of Astellas | September 02, 2010 | Pharma News - Business Wire |
| Seattle Genetics preps for busy fall | August 06, 2010 | FierceBiotech |
| Dendreon Shows Provenge Demand, Seattle Genetics Inks Big Deal, Corey Gets Top Hutch Job, & More Seattle-Area Life Sciences News | August 05, 2010 | Xconomy Life Sciences |
| Seattle Genetics to Present at the Canaccord Genuity 30th Annual Growth Conference | August 04, 2010 | Pharma News - Business Wire |
| Genentech pays $12M to expand Seattle Genetics pact | August 03, 2010 | Health News - BizJournals.com |
| Seattle Genetics scores $900M cancer pact with Genentech | August 03, 2010 | FierceBiotech |
| Seattle Genetics gets $12M in expanded Genentech deal | August 03, 2010 | Health News - BizJournals.com |
| Genentech Agrees to Pay Seattle Genetics Up to $900M for “Empowered Antibodies” | August 03, 2010 | Xconomy Life Sciences |
| Seattle Genetics Expands Antibody-Drug Conjugate Collaboration with Genentech | August 03, 2010 | Biotech News - Business Wire |
| Seattle Genetics trims Q2 loss | July 27, 2010 | Health News - BizJournals.com |
| Seattle Genetics Reports Second Quarter 2010 Financial Results and Continued Pipeline Progress | July 27, 2010 | Biotech News - Business Wire |
| Seattle Genetics and Agensys, an Affiliate of Astellas, Announce Initiation of Phase I Clinical Trial of ASG-5ME for Pancreatic Cancer | July 20, 2010 | Pharma News - Business Wire |
| Seattle Genetics to Host Conference Call and Webcast Discussion of Second Quarter 2010 Financial Results on July 27, 2010 | July 19, 2010 | Pharma News - Business Wire |
| Seattle Genetics Shows Re-Treatment Action | June 05, 2010 | Xconomy Life Sciences |
| Seattle Genetics and Millennium Report Positive Data on Retreatment with Brentuximab Vedotin (SGN-35) in Lymphoma | June 05, 2010 | Pharma News - Business Wire |
| Seattle Genetics Announces Webcast Presentations at Upcoming Investor Conferences | June 02, 2010 | Pharma News - Business Wire |
| Seattle Genetics Grows Up Fast, Valocor Seeks to Fight Acne, Cell Therapeutics Nabs $21M & More Seattle-Area Life Sciences News | May 27, 2010 | Xconomy Life Sciences |
| Seattle Genetics Names Vice President, Sales and Announces Management Promotion | May 24, 2010 | Pharma News - Business Wire |
| Seattle Genetics and Millennium Complete Enrollment of Brentuximab Vedotin (SGN-35) Phase II ALCL Trial | May 24, 2010 | Pharma News - Business Wire |
| Seattle Genetics and Millennium to Present Brentuximab Vedotin (SGN-35) Clinical Data at the American Society of Clinical Oncology Annual Meeting | May 21, 2010 | Pharma News - Business Wire |
| Seattle Genetics Q1 Revenues Up | April 28, 2010 | Biotechnology - Moreover |
| Seattle Genetics sees 1Q profit on partnership | April 27, 2010 | Health News - CNBC |
| Seattle Genetics reports Q1 net income of $11.5M | April 27, 2010 | Health News - BizJournals.com |
| Seattle Genetics Reports First Quarter 2010 Financial Results | April 27, 2010 | Pharma News - Business Wire |
| Seattle Genetics Highlights ADC and SEA Technologies at AACR | April 21, 2010 | Pharma News - Business Wire |
| Seattle Genetics and Agensys, an Affiliate of Astellas, Report ASG-5ME Preclinical Data at AACR | April 21, 2010 | Pharma News - Business Wire |
| Seattle Genetics Gets $9.5M From Genentech | April 21, 2010 | Biotechnology - Moreover |
| Seattle Genetics to Host Conference Call and Webcast Discussion of First Quarter 2010 Financial Results on April 27, 2010 | April 20, 2010 | Pharma News - Business Wire |
| Seattle Genetics gets $9.5M payment from Roche | April 20, 2010 | Health News - CNBC |
| Seattle Genetics in $9.5M deal with Genentech | April 20, 2010 | Health News - BizJournals.com |
| Seattle Genetics Nabs $9.5M | April 20, 2010 | Xconomy Life Sciences |
| Seattle Genetics to Receive $9.5 Million Payment from Genentech to Extend Antibody-Drug Conjugate Collaboration | April 20, 2010 | Pharma News - Business Wire |
| Seattle Genetics Inc starts phase III AETHERA trial of brentuximab vedotin for post-transplant Hodgkin lymphoma | April 08, 2010 | Biotechnology - Moreover |
| Seattle Genetics Expands An... | March 16, 2010 | Biotechnology - Moreover |
| Seattle Genetics to Present at Upcoming Investor Conferences - Zi... | March 12, 2010 | Biotechnology - Moreover |
| Seattle Genetics Adds Patent to 2025 | March 11, 2010 | Xconomy Life Sciences |
| Seattle Genetics Expands Antibody-Drug Conjugate Patent Portfolio | March 11, 2010 | Pharma News - Business Wire |
| Shares of Seattle Genetics Get a Boost, Up 1.1% (SGEN) | March 08, 2010 | Biotechnology - Moreover |
| Seattle Genetics obtains milestone under collaboration with Genentech | March 04, 2010 | Biotechnology - Moreover |
| Seattle Genetics Reaches Genentech Milestone | March 03, 2010 | Contract Pharma |
| Seattle Genetics Gets Roche Cash | March 03, 2010 | Xconomy Life Sciences |
| Seattle Genetics Achieves Milestone under Antibody-Drug Conjugate Collaboration with Genentech | March 03, 2010 | Pharma News - Business Wire |
| Seattle Genetics to Present at Upcoming Investor Conferences | February 25, 2010 | Pharma News - Business Wire |
| Seattle Genetics Reports Fourth Quarter and Year 2009 Financial Results and Provides 2010 Financial Outlook | February 09, 2010 | Pharma News - Business Wire |
| Seattle Genetics Starts Lymphoma Trial | February 03, 2010 | Xconomy Life Sciences |
| Seattle Genetics and Millennium Announce Initiation of Phase I Combination Clinical Trial of Brentuximab Vedotin (SGN-35) for Front-line Hodgkin Lymphoma | February 03, 2010 | Pharma News - Business Wire |
| Seattle Genetics to Host Conference Call and Webcast Discussion of Fourth Quarter and Year 2009 Financial Results on February 9, 2010 | February 02, 2010 | Pharma News - Business Wire |
| Accelerator Slowed Down, Inside the Latest Seattle Genetics Deal, Ekos Finds New Use, & More Seattle-Area Life Sciences News | January 28, 2010 | Xconomy Life Sciences |
| Seattle Genetics raises $135.99 million through public offering of common stock | January 22, 2010 | Biotechnology - Moreover |
| Alder Rises from Ashes, Seattle Genetics Gets Empowered, ZymoGenetics Nets $79M & More Seattle-Area Life Sciences News | January 07, 2010 | Xconomy Life Sciences |
| Seattle Genetics Maps Out a Future With Antibody Drugs That Are “Empowered” | January 06, 2010 | Xconomy Life Sciences |
| Seattle Genetics to Present at the J.P. Morgan Healthcare Conference | January 05, 2010 | Pharma News - Business Wire |
| GSK, Seattle Genetics in ADC Pact | December 22, 2009 | Contract Pharma |
| Seattle Genetics Receives $12M Up Front in Deal with GSK | December 21, 2009 | GEN News Highlights |
| Seattle Genetics Bags $12M From GSK | December 21, 2009 | Xconomy Life Sciences |
| On a roll, Seattle Genetics inks $1.1B in new deals | December 21, 2009 | FierceBiotech |
| Dendreon Nails Down $409M, Stewart Parker Gets Itch to Return, Seattle Genetics Finds New Partner, & More Seattle-Area Life Sciences News | December 17, 2009 | Xconomy Life Sciences |
| Seattle Genetics signs deal worth up to $365M | December 15, 2009 | Health News - BizJournals.com |
| Seattle Genetics Nabs $60M Upfront From Millennium For “Empowered Antibody” | December 15, 2009 | Xconomy Life Sciences |
| Genentech scrubs Seattle Genetics deal | December 11, 2009 | Health News - BizJournals.com |
| Genentech sheds $860M Seattle Genetics pact | December 11, 2009 | FierceBiotech |
| Genentech Ends Collaboration with Seattle Genetics for Phase I Anticancer mAb | December 11, 2009 | GEN News Highlights |
| Roche Scraps Partnership With Seattle Genetics on Lymphoma Drug | December 11, 2009 | Xconomy Life Sciences |
| Seattle Genetics Gets $12M From Agensys | November 23, 2009 | Xconomy Life Sciences |
| Seattle Genetics Announces Antibody-Drug Conjugate Collaboration with GlaxoSmithKline | | Pharma News - Business Wire |
| Seattle Genetics to Host Conference Call on December 15, 2009, to Discuss Brentuximab Vedotin (SGN-35) Partnering | | Pharma News - Business Wire |
| Seattle Genetics Announces Termination of Collaboration Agreement with Genentech for Dacetuzumab (SGN-40) | | Pharma News - Business Wire |
| Seattle Genetics to Present at 2009 Deutsche Bank Biotech Confab | | Pharma News - Business Wire |
| Seattle Genetics Reports Data from Dacetuzumab Phase Ib Combination Clinical Trials | | Pharma News - Business Wire |
| Seattle Genetics Reports Positive Data from Phase I Weekly-Dosing Clinical Trial of Brentuximab Vedotin (SGN-35) in Lymphoma | | Clinical Trials - Business Wire |
| Seattle Genetics to Present Brentuximab Vedotin and Dacetuzumab Data at the 51st American Society of Hematology Annual Meeting and Exposition | | Pharma News - Business Wire |
